Sam Brusco, Associate Editor12.19.23
Butterfly Network and Silicon Valley-based medical robotics company Mendaera began a deal to commercialize a novel robotic system powered by Butterfly’s Ultrasound-on-Chip technology. The deal includes revenue share for every unit sold, following commercialization.
Mendaera’s robotic tech is compatible with Butterfly’s semiconductor-based ultrasound device and is connected through Butterfly’s recently released software development kit, Butterfly Garden. The duo said merging the two will create new category for robotics—a system that can improve precision and consistency for a variety of image-guided, needle-based interventions.
Both companies expect to submit the system to the U.S. Food and Drug Administration (FDA) by 2025.
“Mendaera’s robotic system is perfectly suited to leverage Butterfly’s proprietary Ultrasound-on-Chip by benefiting from the wide array of ultrasonic sensing applications that only our chip can offer,” said Darius Shahida, Butterfly Network’s chief strategy officer. “We are excited to welcome the Mendaera team as a Powered by Butterfly partner and believe our joint solution will expand Butterfly’s reach and clinical impact into the interventional space.”
“At Mendaera, we envision a world where high-quality intervention is available at every care facility, for each and every patient encounter. It was a clear choice for us to collaborate with Butterfly on our technology roadmap, given their unique and programmable Ultrasound-on-Chip platform and aligned mission to make ultrasonic imaging and intervention ubiquitous,” added Josh DeFonzo, co-founder and CEO of Mendaera.
Mendaera’s robotic tech is compatible with Butterfly’s semiconductor-based ultrasound device and is connected through Butterfly’s recently released software development kit, Butterfly Garden. The duo said merging the two will create new category for robotics—a system that can improve precision and consistency for a variety of image-guided, needle-based interventions.
Both companies expect to submit the system to the U.S. Food and Drug Administration (FDA) by 2025.
“Mendaera’s robotic system is perfectly suited to leverage Butterfly’s proprietary Ultrasound-on-Chip by benefiting from the wide array of ultrasonic sensing applications that only our chip can offer,” said Darius Shahida, Butterfly Network’s chief strategy officer. “We are excited to welcome the Mendaera team as a Powered by Butterfly partner and believe our joint solution will expand Butterfly’s reach and clinical impact into the interventional space.”
“At Mendaera, we envision a world where high-quality intervention is available at every care facility, for each and every patient encounter. It was a clear choice for us to collaborate with Butterfly on our technology roadmap, given their unique and programmable Ultrasound-on-Chip platform and aligned mission to make ultrasonic imaging and intervention ubiquitous,” added Josh DeFonzo, co-founder and CEO of Mendaera.